| Accurate structure prediction of biomolecular interactions with AlphaFold 3 J Abramson, J Adler, J Dunger, R Evans, T Green, A Pritzel, ... Nature 630 (8016), 493-500, 2024 | 3315 | 2024 |
| A'rule of three'for fragment-based lead discovery? M Congreve, R Carr, C Murray, H Jhoti Drug discovery today 8 (19), 876-877, 2003 | 1765 | 2003 |
| Fragment-based lead discovery DC Rees, M Congreve, CW Murray, R Carr Nature Reviews Drug Discovery 3 (8), 660-672, 2004 | 1067 | 2004 |
| Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B RLM van Montfort, M Congreve, D Tisi, R Carr, H Jhoti Nature 423 (6941), 773-777, 2003 | 770 | 2003 |
| Recent developments in fragment-based drug discovery M Congreve, G Chessari, D Tisi, AJ Woodhead Journal of medicinal chemistry 51 (13), 3661-3680, 2008 | 763 | 2008 |
| Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine AS Doré, N Robertson, JC Errey, I Ng, K Hollenstein, B Tehan, E Hurrell, ... Structure 19 (9), 1283-1293, 2011 | 658 | 2011 |
| Keynote review: Structural biology and drug discovery M Congreve, CW Murray, TL Blundell Drug discovery today 10 (13), 895-907, 2005 | 505 | 2005 |
| Fragment-based lead discovery: leads by design RAE Carr, M Congreve, CW Murray, DC Rees Drug discovery today 10 (14), 987-992, 2005 | 498 | 2005 |
| Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design M Congreve, SP Andrews, AS Doré, K Hollenstein, E Hurrell, ... Journal of medicinal chemistry 55 (5), 1898-1903, 2012 | 375 | 2012 |
| Impact of GPCR structures on drug discovery M Congreve, C de Graaf, NA Swain, CG Tate Cell 181 (1), 81-91, 2020 | 348 | 2020 |
| Discovery of (2, 4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1, 3-dihydroisoindol-2-yl] methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone … AJ Woodhead, H Angove, MG Carr, G Chessari, M Congreve, JE Coyle, ... Journal of medicinal chemistry 53 (16), 5956-5969, 2010 | 323 | 2010 |
| Application of fragment-based lead generation to the discovery of novel, cyclic amidine β-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency PD Edwards, JS Albert, M Sylvester, D Aharony, D Andisik, O Callaghan, ... Journal of medicinal chemistry 50 (24), 5912-5925, 2007 | 266 | 2007 |
| Progress in structure based drug design for G protein-coupled receptors M Congreve, CJ Langmead, JS Mason, FH Marshall Journal of medicinal chemistry 54 (13), 4283-4311, 2011 | 263 | 2011 |
| Intracellular allosteric antagonism of the CCR9 receptor C Oswald, M Rappas, J Kean, AS Doré, JC Errey, K Bennett, F Deflorian, ... Nature 540 (7633), 462-465, 2016 | 255 | 2016 |
| Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation AL Gill, M Frederickson, A Cleasby, SJ Woodhead, MG Carr, ... Journal of medicinal chemistry 48 (2), 414-426, 2005 | 242 | 2005 |
| Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency CW Murray, MG Carr, O Callaghan, G Chessari, M Congreve, S Cowan, ... Journal of medicinal chemistry 53 (16), 5942-5955, 2010 | 234 | 2010 |
| Crystal structure of the GLP-1 receptor bound to a peptide agonist A Jazayeri, M Rappas, AJH Brown, J Kean, JC Errey, NJ Robertson, ... Nature 546 (7657), 254-258, 2017 | 219 | 2017 |
| Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors N Howard, C Abell, W Blakemore, G Chessari, M Congreve, S Howard, ... Journal of medicinal chemistry 49 (4), 1346-1355, 2006 | 206 | 2006 |
| Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design JA Christopher, J Brown, AS Doré, JC Errey, M Koglin, FH Marshall, ... Journal of medicinal chemistry 56 (9), 3446-3455, 2013 | 193 | 2013 |
| New insights from structural biology into the druggability of G protein-coupled receptors JS Mason, A Bortolato, M Congreve, FH Marshall Trends in pharmacological sciences 33 (5), 249-260, 2012 | 192 | 2012 |
Fiona MarshallPresident Biomedical Research NovartisVerified email at novartis.com
